Biopharma Daily Stock Updates - 04/21/21

$XBI $132.77 +3.49%

$OCGN +6.5% Co-development partner shared positive Phase 3 results on COVAXIN. source

$DVAX +5.0% VA2001 Phase 3 trial initiated; expect data and regulatory submission in autumn 2021. source

$TRVN +2.9% TRV027 COVID-19 asset selected for inclusion in international, multi-site, Phase 2/3 trial. source

$SNDX +10.7% Announces positive interim data in Phase 1 portion of AUGMENT-101 trial. source

$EVFM +10.6% Will present at NCODA 2021 National Forum 4/28-30. source

$ORMP +10.6% Will present at Alliance Global Partners on 4/26/2021. source

$ALLO +7.8% ALLO-715 granted RMAT Designation. source

$PHVS +4.5% IND accepted for additional study with PHVS416. source

$VIR -1.0% and $VBIV +7.7% Phase 2 combination trial of VBI-2601 with VIR-2218 initiated dosing. source

$RVMD +5.6% Dosed first patient in RMC-5552 Phase 1/1b trial. source

$TGTX +1.9% ULTRA-V Phase 3 trial initiated; results from Phase 1 trial expected later in 2021. source

$SLS +9.3% President and CEO discusses Phase 3 asset GPS as a monotherapy. source

$EOLS +11.1% Commenced proposed public offering of common stock. source